CALU

Across TCGA pan-cancer cohorts, CALU mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CALU data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CALU mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CALU expression acts as an unfavorable survival marker.

CCRCC, LSCC, and UCEC are the cancer types where CALU mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.598	0.876	<.001	95	view →
LSCC	DFS	Tertile	II,III,IV	0.373	0.919	<.001	60	view →
UCEC	OS	Tertile	All	0.902	1.000	.024	4	view →
GBM	DFS	Quartile	All	0.255	0.473	.032	2	view →
HNSC	OS	Median	IV	0.640	0.818	.042	1	view →
LUAD	OS	Quartile	All	0.757	0.926	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CALU–CCRCC (DFS)

Open the CCRCC breakdown →